Who Should Sponsor?

 

WHO ATTENDS

Pharma, biotechs

  • VP Clinical Development
  • Chief Medical Officer
  • Chief Scientific Officer
  • Regulatory Affairs
  • President, Head of Rare Diseases

TOPIC AREAS

- Patient centric clinical development

- Clinical trial design

- Real World Evidence in clinical development

- Expanded Access Programs / Managed Access Programs

WHO SHOULD SPONSOR

- Contract Research Organizations (CROs)

- Contract Development and Manufacturing Organizations (CDMOs)

- Clinical Trials Services - Home Clinical Trials

- Patient Recruitment & Identification

- Regulatory Consulting

WHO ATTENDS

Pharma, biotechs

  • Chief Patient Officer
  • VP Patient Advocacy
  • Medical Affairs
  • Patient Engagement

Patient Advocacy Groups

TOPICS AREAS

- Patient Data

- Patient Registries & Patient Reported Outcomes (PROs)

- Evolving role of patient groups in R&D

- Genetic testing & diagnosis

- Advocacy & Policy

- Setting up patient groups

- Industry collaboration

WHO SHOULD SPONSOR

- Pharma & biotechs

- Research Institutions

- Patient Registries

- Patient Engagement Platforms

- Genetic Testing providers

- Genomic Sequencing Platforms

- Diagnostics

WHO ATTENDS

Pharma, biotechs

  • VP Gene Therapy
  • Chief Medical Officer
  • Chief Manufacturing Officer
  • Chief Scientific Officer
  • VP Manufacturing

Technical Operations

TOPICS AREAS

- Gene therapy development

- Cell therapy development

- Translational science and path to clinical trials

- Regulation

WHO SHOULD SPONSOR

- Advanced therapies pharma & biotechs

- Gene Editing biotechs

- Contract Research Organizations (CROs)

- Clinical trial design

WHO ATTENDS

Pharma, biotechs

  • Chief Executive Officer
  • VP, Head of Market Access
  • VP, Head of Pricing and Reimbursement
  • VP of Health Economics/HEOR
  • VP of HTA
  • Head of Value Demonstration
  • VP, Evidence and Data
  • Payers (public and private)
  • Government & Regulatory agencies

TOPICS AREAS

- Advanced therapies pricing & reimbursement

- Real World Evidence

- Health Technology Assessment

- Value Based Assessment

- Next generation pricing and innovative pricing models

WHO SHOULD SPONSOR

- PRO consultancies and PRO technology providers

- Value communication organizations

- Pricing & Reimbursement consulting firms

- HEOR service providers

- Patient registries and database providers

WHO ATTENDS

Pharma, biotechs

  • Chief Data Officer
  • Chief Technology Officer
  • Chief Operating Officer
  • VP, Analytics
  • Head of Innovation
  • Head of Digital

Hospitals and healthcare centers

Payers

TOPICS AREAS

- AI in drug discovery

- Patient identification

- Data analytics

- Data collection through wearables and applications

WHO SHOULD SPONSOR

- Artificial Intelligence platforms

- Patient identification solutions

- Machine learning

- Data analytics

- Wearable technology

- Digital Health Apps

- Patient registries

WHO ATTENDS

Pharma, biotechs

  • CEO
  • Presidents
  • Chief Business Officer
  • VP Business Development
  • VP External Innovation
  • VP R&D

Venture Capital Firms

Grant Agencies (Public and Private)

Licensing pharma

TOPICS AREAS

- Advanced therapies investment

- Risk assessment

- Partnering and co-development opportunities

- Funding

- Accelerating orphan drug development

- Successful case studies

WHO SHOULD SPONSOR

- Advanced therapies investment

- Risk assessment

- Partnering and co-development opportunities

- Funders

WHO ATTENDS

Pharma, biotechs

  • Chief Commercial Officer
  • VP Commercial Operations
  • VP of Marketing
  • VP Medical Affairs

TOPIC AREAS

- Business models

- Forecasting and Epidemiology

- Global expansion and internationalization

- Business development

WHO SHOULD SPONSOR

- Specialty Pharmacy

- Logistics, Supply Chain, 3PL

- Strategic Consulting

- Real World Evidence

- Forecasting and Epidemiology

- Marketing, Communications Agency

WHO ATTENDS

Pharma, biotechs

  • Presidents & Heads of Patient Diagnosis Programs
  • R&D Strategic Alliance

Rare Disease advocacy organizations

  • Newborn Screening

TOPIC AREAS

- Genetic counselling

- Industry partnerships

- Genomics

- Newborn Screening

- Access & Reimbursement of testing

WHO SHOULD SPONSOR

- Genetic testing companies

- Genetic counselling consulting

- Genomics companies

- Newborn screening providers

WHO ATTENDS

Pharma, biotechs

  • Chief Operating Officer
  • Chief Manufacturing & Technology Officer
  • VP Technical Operations
  • VP of CMC
  • VP Manufacturing
  • VP of Process Development
  • VP of Quality Control

TOPIC AREAS

- Process development

- Outsourcing

- Viral vector development

- Manufacturing efficiency and capacity

- Analytical development

- Quality Control

WHO SHOULD SPONSOR

- Process development

- Outsourcing

- Viral vector development

- Manufacturing efficiency and capacity

- Analytical development

WHO ATTENDS

Pharma, biotechs

  • VP Market Access
  • Pricing and Reimbursement
  • Chief Commercial Officer
  • International Business

Regulators

Government

  • Ministry of Health
  • Policy makers

TOPIC AREAS

- Market entry strategies

- Stakeholder collaboration for market access

- Real World Evidence

- Improving access

- International regulation

WHO SHOULD SPONSOR

- Market entry strategies

- Stakeholder collaboration for market access

- Real World Evidence

- Improving access

- International regulation

WHO ATTENDS

Pharma, biotechs

  • Heads of Discovery
  • VP Clinical Development
  • Chief Medical Officer
  • Chief Scientific Officer
  • Regulatory Affairs
  • President, Head of Rare Diseases

TOPIC AREAS

- Discovery platforms

- Artificial Intelligence & Machine Learning applications

- Small molecule development

- Scientific innovations

- Collaborations

WHO SHOULD SPONSOR

- Drug discovery companies

- Artificial Intelligence and Machine Learning applications

- Predictive analytics platforms

- Contract Research Organizations (CROs)

WHO ATTENDS

Pharma, biotechs

  • VP Cell Therapy
  • Head of Oncology
  • Head of Immunotherapy 
  • Chief Medical Officer

TOPIC AREAS

- Diagnosis

- Biomarker R&D

- CAR-T development

- Advocacy and patient voice

- Clinical development and commercialization

WHO SHOULD SPONSOR

- Immunoncology pharma and biotechs

- Contract Manufacturing Organizations (CMOs)

- Contract Research Organizations (CROs)

- Genomic/DNA sequencing

 

 

 

PAYERS SEMINAR

On this seminar, payers from around the world will discuss approaches and strategies to improve pricing & reimbursement in rare diseases, including innovative pricing schemes and optimization of value-based assessments.

NEXT GEN THERAPIES SEMINAR

Learn about novel pipelines, approaches and candidates on the Next Generation Therapies Seminar, where someday these technologies and therapies could be the common place to treat rare diseases.

PATIENT DATA SEMINAR

When developing therapies for rare and ultra-rare diseases the value of patient data is immensurable. Though patients and their families are usually willing to share their data to advance research being their individual causes, issues with data privacy, ownership, consent and handling are still a big hurdle impeding the progress of utilizing data to identify patients, shorten the time for an accurate diagnosis, build disease knowledge, expedite R&D, and enhance access to available therapies. assessments.

 

 

Get Involved At World Orphan Drug Congress USA

 

To Sponsor Or Exhibit

 
 

Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506

 

 

 

To Speak

 
 

Claire Murphy
claire.murphy@terrapinn.com
t/ +1 646 619 1784

 

 

 

Marketing & Press Opportunities

 
 

Taylor Post 
taylor.post@terrapinn.com
t/ +1 646 619 1785